Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mayes

Showing results (341-350 of 382) with videos related to

Pageof 39
Sort By:
Medicine|February 3, 2018
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical databaseNadia D Morgan, Ami A Shah, Maureen D Mayes, et al.
Annals of the Rheumatic Diseases|October 10, 2009
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in CaucasiansB Rueda, P Gourh, J Broen, et al.
Annals of the American Thoracic Society|April 10, 2025
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United StatesYiming Luo, Shervin Assassi, Maureen D Mayes, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
JMIR Research Protocols|April 25, 2020
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility TrialMarie-Eve Carrier, Linda Kwakkenbos, Warren R Nielson, et al.
Pilot and Feasibility Studies|February 27, 2022
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) ProgramLinda Kwakkenbos, Nora Østbø, Marie-Eve Carrier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohortsIqtidar Hanif, Shervin Assassi, Maureen D Mayes, et al.
Arthritis Research & Therapy|January 10, 2014
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibilityElena López-Isac, Lara Bossini-Castillo, Carmen P Simeon, et al.
Pageof 39

Showing results (341-350 of 382) with videos related to

Sort By:
Pageof 39
Medicine|February 3, 2018
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical databaseNadia D Morgan, Ami A Shah, Maureen D Mayes, et al.
Annals of the Rheumatic Diseases|October 10, 2009
BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in CaucasiansB Rueda, P Gourh, J Broen, et al.
Annals of the American Thoracic Society|April 10, 2025
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United StatesYiming Luo, Shervin Assassi, Maureen D Mayes, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
JMIR Research Protocols|April 25, 2020
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility TrialMarie-Eve Carrier, Linda Kwakkenbos, Warren R Nielson, et al.
Pilot and Feasibility Studies|February 27, 2022
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) ProgramLinda Kwakkenbos, Nora Østbø, Marie-Eve Carrier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohortsIqtidar Hanif, Shervin Assassi, Maureen D Mayes, et al.
Arthritis Research & Therapy|January 10, 2014
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibilityElena López-Isac, Lara Bossini-Castillo, Carmen P Simeon, et al.
Pageof 39